Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.

The Journal of infectious diseases - 15 Mar 2016

Harari Ariana, Chen Zigui, Rodríguez Ana Cecilia, Hildesheim Allan, Porras Carolina, Herrero Rolando, Wacholder Sholom, Panagiotou Orestis A, Befano Brian, Burk Robert D, Schiffman Mark

Abstract excerpt

BACKGROUND: Results from the Costa Rica Vaccine Trial (CVT) demonstrated partial cross-protection by the bivalent human papillomavirus (HPV) vaccine, which targets HPV-16 and HPV-18, against HPV-31, -33, and -45 infection and an increased incidence of HPV-51 infection. METHODS: A study nested within the CVT intention-to-treat cohort was designed to assess high-risk HPV variant lineage-specific vaccine efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Papillomavirus Vaccines

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 26518044
DOI: 10.1093/infdis/jiv519
PMCID: PMC4760417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.PMID 26518044Read ↗

Human Papillomavirus (HPV) Vaccines: Limited Cross‐Protection against Additional HPV TypesSemantic proximity Read ↗

Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.Semantic proximity Read ↗

A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical NeoplasiaSemantic proximity Read ↗

Human papillomavirus vaccines and the potential for cross-protection between related HPV typesSemantic proximity Read ↗

Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV.Semantic proximity Read ↗

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18Semantic proximity Read ↗

Comparison of the immunogenicity of Cervarix<sup>®</sup>and Gardasil<sup>®</sup>human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adultsSemantic proximity Read ↗

Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.Semantic proximity Read ↗

Recurring infection with ecologically distinct human papillomavirus (HPV) types explains high prevalence and diversitySemantic proximity Read ↗

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.Semantic proximity Read ↗

Recurring infection with ecologically distinct HPV types can explain high prevalence and diversitySemantic proximity Read ↗

Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.